TNP-470 Reduces Glioblastoma Angiogenesis in Three Dimensional GelMA Microwell Platform
Abstract:
Tumor angiogenesis is a promising target for cancer treatment, because severing the supply of oxygen and nutrients to tumors halts tumor growth. Unfortunately, many anticancer drugs, including angiogenesis inhibitors, fail in clinical trials, despite showing high efficiency during in vitro and in vivo experiments. This inconsistency from in vitro and in vivo experiments to clinical trials represents a major obstacle in drug development and cancer treatment. Therefore, we set out to demonstrate how our rapid, stable, easy-to-use three-dimensional (3-D) in vitro angiogenesis model can be used to investigate tumor formation and implement drug screening. In this study, we utilized a 3-D in vitro angiogenesis model, based on gelatin methacrylate (GelMA) hydrogel microwells, to mimic the native microenvironment of tumor angiogenesis. Using this model, we were able to quantify the immigration of endothelial cells into a cancer spheroid during the angiogenic process. Next, we tested the anti-angiogenic effect of the angiogenesis inhibitor, TNP-470, on the cancer spheroids in the model. Based on our results, we believe that this novel in vitro system can be widely used for the high-throughput screening of other anti-angiogenic drugs, and could contribute to the development of personalized medicine in the future.
Insights
A new 3-D in vitro model using GelMA hydrogel microwells accurately mimics tumor angiogenesis. This system enables efficient drug screening for novel anti-angiogenic cancer therapies.
Area of Science:
- Biomedical Engineering
- Cancer Research
- Drug Development
Background:
- Tumor angiogenesis is crucial for cancer growth, making it a key therapeutic target.
- Many anti-cancer drugs, including angiogenesis inhibitors, show discrepancies between preclinical and clinical trial results.
- Bridging this gap requires advanced in vitro models that better replicate the tumor microenvironment.
Purpose of the Study:
- To develop and validate a rapid, stable, and user-friendly 3-D in vitro angiogenesis model.
- To investigate tumor formation and assess anti-angiogenic drug efficacy.
- To establish a platform for high-throughput drug screening and personalized medicine.
Main Methods:
- Utilized a 3-D in vitro angiogenesis model based on gelatin methacrylate (GelMA) hydrogel microwells.
- Mimicked the native tumor microenvironment to study angiogenesis.
- Quantified endothelial cell migration into cancer spheroids and tested the efficacy of TNP-470.
Main Results:
- Successfully mimicked tumor angiogenesis in a 3-D in vitro environment.
- Quantified endothelial cell invasion into cancer spheroids.
- Demonstrated the anti-angiogenic effect of TNP-470 within the model.
Conclusions:
- The developed 3-D GelMA hydrogel microwell system effectively models tumor angiogenesis.
- This novel in vitro system is suitable for high-throughput screening of anti-angiogenic drugs.
- The model holds potential for advancing personalized medicine in cancer treatment.
